Related Experiment Video

Updated: Jun 21, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Human brain tumor imaging with a protein-binding MR contrast agent: initial experience

Marco Essig1, Martin Rohrer, Frederik Giesel

  • 1Department of Radiology, German Cancer Research Center, INF 280, 69120 Heidelberg, Germany. m.essig@dkfz.de

European Radiology
|August 13, 2009
PubMed
Summary

Gadofosveset, a novel Gd-based contrast agent, shows comparable enhancement for intracranial tumors to conventional agents. Its prolonged effect may improve imaging of subtle or non-enhancing tumors.

More Related Videos

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging06:44

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging

Published on: June 7, 2020

Hybrid µCT-FMT imaging and image analysis13:45

Hybrid µCT-FMT imaging and image analysis

Published on: June 4, 2015

Related Concept Videos

Magnetic Resonance Imaging01:24

Magnetic Resonance Imaging

Magnetic resonance imaging (MRI) is a noninvasive medical imaging technique based on a phenomenon of nuclear physics discovered in the 1930s, in which matter exposed to magnetic fields and radio waves was found to emit radio signals. In 1970, a physician and researcher named Raymond Damadian noticed that malignant (cancerous) tissue gave off different signals than normal body tissue. He applied for a patent for the first MRI scanning device in clinical use by the early 1980s. The early MRI...